| Name | PCSK9-IN-10 |
| Description | PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications. |
| In vitro | PCSK9-IN-10 (0, 2.5, 5, 12.5, 25 µM ; 24 h) significantly reduces PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose-dependent manner.[1] |
| In vivo | PCSK9-IN-10 (30 mg/kg; oral administration; once daily for 8 weeks) reduces total cholesterol (TC) levels and atherosclerotic plaque size in ApoE KO mice.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (13.39 mM), Sonication is recommended. DMSO : 225.0 mg/mL (602.6 mM), Sonication is recommended.
|
| Keywords | threoninkinase | threonin kinase | Serinekinase | Serine kinase | Ser/Thr Protease | PCSK9-IN-10 | PCSK9IN10 | PCSK9 |
| Inhibitors Related | Piceatannol | Bicyclol | Propane-1,2,3-triyl tripalmitate | Chymotrypsin | Fasudil hydrochloride | Camostat mesylate | SRPIN340 | 6-(Dimethylamino)purine | FOY 251 | BMT-124110 Formate | Benzamidine hydrochloride | Cetraxate hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |